Beijing: China's National Health Commission, along with 13 other government departments, has issued a directive aimed at curbing malpractice in pharmaceutical procurement, sales, and medical services for 2025. The initiative marks a significant step towards addressing systemic issues within the nation's healthcare system.

According to Namibia Press Agency, the directive focuses on cracking down on illegal activities in assisted reproduction, cosmetic procedures, and the issuance of medical certificates, among other fields. The effort aims to combat misconduct such as online medical scams, where individuals pose as patients to promote unlicensed clinics, as well as the promotion of products under the guise of academic activities.

Outlining 15 key tasks, the directive calls for stricter oversight of high-risk areas. It urges stronger administrative law enforcement and more rigorous judicial handling of cases, emphasizing "zero tolerance" for medical personnel who violate professional ethics, infringe on the rights of patients and the public, or tarnish the reputation of the healthcare industry.

Authorities are encouraged to continuously promote legal awareness campaigns, foster public participation in oversight, and consistently improve government oversight, according to the directive. This comprehensive approach seeks to restore trust and integrity in China's healthcare sector.